Clinical Trials

March 27, 2013

PAHTCH – Pulmonary Arterial Hypertension Treatment with Carvedilol for Heart Failure

  • Study Sponsor: National Institutes of Health
  • Institution: The Cleveland Clinic
  • Start Date: 12/2012
  • End Date: 07/2017
  • Design: placebo-controlled
  • Age Range (years): from 18 to 65
  • Type of PH
    • All PAH (Group 1 PH)
  • Study Duration for Individual Patient: 6 months
  • Contact: Emir Roach at 216-445-7706 or
  • Listing on

FacebookGoogle +TwitterLinkedInPinterestInstagramYouTubeBloggerFeedsPHAware Download our App

The information provided on the PHA website is provided for general information only. It is not intended as legal, medical or other professional advice, and should not be relied upon as a substitute for consultations with qualified professionals who are familiar with your individual needs.

801 Roeder Road, Ste. 1000, Silver Spring, MD 20910   Patient-to-Patient Support Line: 1-800-748-7274
    Privacy Policy    Provide Feedback & Report Bugs

Designed by Matrix Group International, Inc.® | © 2015 Pulmonary Hypertension Association. All Rights Reserved.


The National Organization for Rare Disorders (NORD) awarded PHA the Abbey S. Meyers Leadership Award in 2012 for outstanding service to PHA members in advocacy, education and other key areas.